Rauniyar
Vivek Rauniyar, Berkeley, CA US
Patent application number | Description | Published |
---|---|---|
20140350253 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST - The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reagents has enabled a vast set of enantioselective transformations. A largely overlooked analogous mechanism wherein a chiral anionic catalyst brings a cationic species into solution is itself a powerful method. The concept is broadly applicable to a number of different reaction pathways, including to the enantioselective fluorocyclization of olefins, and dearomatization of aromatic systems with a cationic electrophile-transferring (e.g., fluorinating) agent and a chiral phosphate catalyst. The reactions proceed in high yield and stereoselectivity. The compounds and methods of the invention are of particular value, especially considering the scarcity of alternative approaches. | 11-27-2014 |
Vivek Rauniyar, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150126490 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS - The present invention provides a compound of Formula (I) or a salt thereof; | 05-07-2015 |
20150274733 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics | 10-01-2015 |
Vivek Rauniyar US
Patent application number | Description | Published |
---|---|---|
20150274733 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics | 10-01-2015 |